Amarin Corporation plc (AMRN) Stock Analysis & Investment Frameworks
Amarin Corporation plc (AMRN) stock analysis on Invetso. Review Amarin Corporation plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Amarin Corporation plc Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: IE
Amarin Corporation plc Key Financial Metrics
- Market Cap: $241.78M
- Revenue: $213.65M
- ROE: -4.26%
- ROIC: -5.33%
- Dividend Yield: N/A
About Amarin Corporation plc
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.